TREATMENT ARM: Full dose
Phase 2
TREATMENT ARM: Full dose is one of 8 therapeutic programs targeting PTSD. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
9 competitors in PTSD
#DrugCompanyPhaseTrials
1Nurtec
PfizerApproved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ritalin
NovartisPhase 2
Psilocybin
COMPASS PathwaysPhase 2
Reboxetine
UUniversity of Zurich
Phase 2
TREATMENT ARM: Full dose
UU.S. Army Medical Research and Development Command
Phase 2
Psychedelic
CCanadian Forces Health Services Centre Ottawa
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
PTSD1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for TREATMENT ARM: Full dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]